GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shattuck Labs Inc (NAS:STTK) » Definitions » Cash Flow from Investing

STTK (Shattuck Labs) Cash Flow from Investing : $40.37 Mil (TTM As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Shattuck Labs Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2025, Shattuck Labs spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $15.60 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Shattuck Labs gained $15.60 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2025.


Shattuck Labs Cash Flow from Investing Historical Data

The historical data trend for Shattuck Labs's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shattuck Labs Cash Flow from Investing Chart

Shattuck Labs Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Investing
Get a 7-Day Free Trial -146.32 -10.44 49.44 110.86 -8.51

Shattuck Labs Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.28 -5.41 -0.82 31.00 15.60

Shattuck Labs Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Shattuck Labs's Cash Flow from Investing for the fiscal year that ended in Dec. 2024 is calculated as:

Shattuck Labs's Cash Flow from Investing for the quarter that ended in Mar. 2025 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $40.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shattuck Labs  (NAS:STTK) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Shattuck Labs's purchase of property, plant, equipment for the three months ended in Mar. 2025 was $0.00 Mil. It means Shattuck Labs spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Shattuck Labs's sale of property, plant, equipment for the three months ended in Mar. 2025 was $0.00 Mil. It means Shattuck Labs gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Shattuck Labs's purchase of business for the three months ended in Mar. 2025 was $0.00 Mil. It means Shattuck Labs spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Shattuck Labs's sale of business for the three months ended in Mar. 2025 was $0.00 Mil. It means Shattuck Labs gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Shattuck Labs's purchase of investment for the three months ended in Mar. 2025 was $0.00 Mil. It means Shattuck Labs spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Shattuck Labs's sale of investment for the three months ended in Mar. 2025 was $15.60 Mil. It means Shattuck Labs gained $15.60 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Shattuck Labs's net Intangibles purchase and sale for the three months ended in Mar. 2025 was $0.00 Mil. It means Shattuck Labs paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Shattuck Labs's cash from discontinued investing activities for the three months ended in Mar. 2025 was 0.00 Mil. It means Shattuck Labs paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Shattuck Labs's cash from other investing activities for the three months ended in Mar. 2025 was $0.00 Mil. It means Shattuck Labs paid $0.00 Mil for other investing activities.


Shattuck Labs Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Shattuck Labs's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Shattuck Labs Business Description

Traded in Other Exchanges
N/A
Address
500 W. 5th Street, Suite 1200, Austin, TX, USA, 78701
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Executives
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Taylor Schreiber director, officer: Chief Executive Officer 100 EUROPA DRIVE, CHAPEL HILL NC 27517
Tyler Brous director 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Stephen Stout officer: See Remarks C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701
Andrew R Neill officer: See Remarks 1018 W 11TH STREET, SUITE 100, AUSTIN TX 78703
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Abhinav A. Shukla officer: Chief Technical Officer 500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701
Carrie Brownstein director 500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701
Erin Ator Thomson officer: General Counsel 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Josiah Hornblower director, 10 percent owner, officer: Chairman 3317 BOWMAN AVE, AUSTIN TX 78703
Neil W Gibson director C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Helen M Boudreau director 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Arundathy N. Pandite officer: Chief Medical Officer 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Victor Stone director 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Casi Deyoung officer: Chief Business Officer C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744